The scoreboard, and what is not on it. The hard targets, how often each is actually
looked at, and the quiet signals that never reach a dashboard.
Portfolio Advancement Rate
Number of research programmes successfully moving from one stage (e.g., Discovery) to the next (e.g., Pre-clinical Development) within the agreed timelines.
Target · Advance at least one new programme into formal development annually, plus 2-3 significant internal milestones across existing programmes. In Q2, a lead candidate from the Oncology programme successfully met all pre-clinical go/no-go criteria, moving into formal toxicology studies, ahead of schedule.
R&D Budget Adherence
Managing your departmental budget, including headcount, capital expenditure, and external spend (CROs, reagents), within agreed tolerances.
Target · Maintain actual spend within ±5% of the approved annual budget (£2M-£10M+). For the last financial year, the Neurosciences R&D budget of £3.5M was managed to £3.48M, representing a 0.6% underspend, without compromising key deliverables.
Intellectual Property (IP) Generation
The number of new patent applications or significant invention disclosures generated by the teams under your leadership, reflecting novel scientific output.
Target · Contribute to 3-5 new patent filings or significant invention disclosures per year. In 2023, your department filed four new patent applications covering novel assay methods and a new class of therapeutic compounds, strengthening our IP portfolio.
Project Go/No-Go Decision Quality
The percentage of projects that, once a 'go' decision is made, successfully progress through subsequent stages without significant scientific or technical roadblocks that should have been identified earlier.
Target · Achieve an 80% success rate for projects that pass the 'go' gate and proceed to the next development stage. Out of 10 projects given the 'go' for pre-clinical development, 8 successfully completed the next phase without major scientific re-work, indicating strong decision-making at the gate.
Strategic Influence & Leadership
Your ability to shape the overall R&D strategy, influence senior leadership (including the Board), and represent the company's scientific vision externally.
- Regularly invited to present at Board meetings on R&D pipeline updates
- sought out by the C-Suite for input on company-wide strategic planning
- recognised externally through speaking engagements or publications
- successful negotiation of significant R&D partnerships.
Talent Development & Retention
The effectiveness of your leadership in attracting, developing, and retaining top scientific talent within your department, and building a strong succession plan.
- Low voluntary attrition rates for high-performing scientists
- successful internal promotions to Group Leader or Senior Scientist roles
- positive feedback in annual engagement surveys regarding career development opportunities
- clear succession plans for critical roles within your remit.
Scientific & Operational Excellence
Ensuring the highest standards of scientific rigor, data integrity, and operational efficiency across all research programmes and laboratories under your direction.
- Successful internal and external GxP audits with minimal findings
- adoption of best practices in experimental design and data analysis across teams
- demonstrable improvements in lab efficiency (e.g., reduced reagent waste, faster turnaround times for key assays)
- publications in high-impact journals.